| Drug General Information |
| Drug ID |
D0EJ3B
|
| Former ID |
DNCL002367
|
| Drug Name |
AMG 900
|
| Drug Type |
Small molecular drug
|
| Indication |
Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48]
|
Phase 1 |
[1],
[2]
|
|---|
| Company |
Amgen Thousand
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C28H21N7OS
|
| InChI |
InChI=1S/C28H21N7OS/c1-17-15-24(37-16-17)25-20-5-2-3-6-21(20)26(35-34-25)32-18-8-10-19(11-9-18)36-27-22(7-4-13-30-27)23-12-14-31-28(29)33-23/h2-16H,1H3,(H,32,35)(H2,29,31,33)
|
| InChIKey |
IVUGFMLRJOCGAS-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
50085297, 57153227, 123055443, 135727848, 136340314, 136367484, 137275938, 138171610, 144115599, 152258491, 160647326, 162011353, 162038106, 162202641, 163642970, 164193995, 172095415, 174531643, 185969977, 189622853, 198981726, 223705215, 224563073, 226817947, 242060341, 242559915, 245945322, 249565740, 251962962, 252110169, 252160447, 252214714
|
| Target and Pathway |
| Target(s) |
Aurora protein kinase |
Target Info |
Modulator |
[1]
|
|---|
| Aurora kinase B |
Target Info |
Modulator |
[1]
|
| Aurora kinase A |
Target Info |
Modulator |
[1]
|
|
KEGG Pathway
|
Oocyte meiosishsa04114:Oocyte meiosis
|
|
Pathway Interaction Database
|
Aurora B signaling
|
|
Signaling by Aurora kinases
|
|
Aurora C signaling
|
|
FOXM1 transcription factor network
|
|
Aurora A signalingaurora_b_pathway:Aurora B signaling
|
|
Integrin-linked kinase signaling
|
|
PLK1 signaling events
|
|
Aurora A signaling
|
|
Reactome
|
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Separation of Sister Chromatids
|
|
Resolution of Sister Chromatid Cohesion
|
|
RHO GTPases Activate ForminsR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
RHO GTPases Activate Formins
|
|
Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
|
|
Regulation of PLK1 Activity at G2/M Transition
|
|
WikiPathways
|
EGF/EGFR Signaling Pathway
|
|
JAK/STAT
|
|
Gastric Cancer Network 1
|
|
Integrated Breast Cancer Pathway
|
|
APC/C-mediated degradation of cell cycle proteinsWP2757:Mitotic Metaphase and Anaphase
|
|
Mitotic Prometaphase
|
|
Regulation of Microtubule Cytoskeleton
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway
|
|
APC/C-mediated degradation of cell cycle proteins
|
| References |
| REF 1 | Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54. |
|---|
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8060). |
|---|
